Dr. Wisnivesky is a pulmonologist and clinical epidemiologist whose research focuses on asthma, cancer epidemiology and outcomes research. He is the Chief of the Division of General Internal Medicine. Dr. Wisnivesky has been the Principal Investigator (PI) of three R01s to conduct secondary data analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to evaluate the diagnosis, staging, and treatment of lung cancer. He is also the PI of an American Cancer Society funded cohort study assessing the determinants of disparities in the diagnosis and treatment of lung cancer. Dr. Wisnivesky has considerable experience using the SEER registry and the SEER-Medicare database. He has published several manuscripts using these databases addressing issues related to the diagnosis, treatment, disparities in care, and outcomes of patients with lung cancer.
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
News Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients. Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Language
English
Position
PROFESSOR | Medicine, General Internal Medicine
Hospital Affiliations
The Mount Sinai Hospital
About Me
Dr. Wisnivesky is a pulmonologist and clinical epidemiologist whose research focuses on asthma, cancer epidemiology and outcomes research. He is the Chief of the Division of General Internal Medicine. Dr. Wisnivesky has been the Principal Investigator (PI) of three R01s to conduct secondary data analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to evaluate the diagnosis, staging, and treatment of lung cancer. He is also the PI of an American Cancer Society funded cohort study assessing the determinants of disparities in the diagnosis and treatment of lung cancer. Dr. Wisnivesky has considerable experience using the SEER registry and the SEER-Medicare database. He has published several manuscripts using these databases addressing issues related to the diagnosis, treatment, disparities in care, and outcomes of patients with lung cancer.
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
News Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients. Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Language
English
Position
PROFESSOR | Medicine, General Internal Medicine
Hospital Affiliations
The Mount Sinai Hospital
About Me
Dr. Wisnivesky is a pulmonologist and clinical epidemiologist whose research focuses on asthma, cancer epidemiology and outcomes research. He is the Chief of the Division of General Internal Medicine. Dr. Wisnivesky has been the Principal Investigator (PI) of three R01s to conduct secondary data analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to evaluate the diagnosis, staging, and treatment of lung cancer. He is also the PI of an American Cancer Society funded cohort study assessing the determinants of disparities in the diagnosis and treatment of lung cancer. Dr. Wisnivesky has considerable experience using the SEER registry and the SEER-Medicare database. He has published several manuscripts using these databases addressing issues related to the diagnosis, treatment, disparities in care, and outcomes of patients with lung cancer.
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
News Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients. Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Language
English
Position
PROFESSOR | Medicine, General Internal Medicine
Hospital Affiliations
The Mount Sinai Hospital
Video
Education
MD, Universidad de Buenos Aires
MD, University of Buenos Aires, Argentina
MPH, Columbia University
DrPH, Columbia University
Residency, Internal Medicine
Montefiore Medical Center
Fellowship, Pulmonary and Critical Care Medicine
New York Presbyterian Hospital-Weill Cornell
Awards
2010
Research Excellence Award
Department of Medicine, MSSM
2009
Joseph L. Fleiss Prize Biostatistics , Columbia University
1998
Young Investigator Award
CHEST
1998
J. Burns Amberson Fellow
American Lung Association of New York
1996
Outstanding House Officer Award
Montefiore Medical Center, Albert Einstein College of Medicine
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wisnivesky during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
PPD
Banook
Prospero
sanofi-aventis
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Merus Pharmaceutical
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.